Search results

Clinical Neuroscience

SEPTEMBER 30, 2017

Health anxiety mediates the connection between somatosensory amplification and self-reported food sensitivity

ELIESON M. Linn, DÖMÖTÖR Zsuzsanna, KÖTELES Ferenc

Background - The frequency of self-reported food sensitivity (SFS) is increasing, and has a negative impact on the well-being and everyday functioning of the affected people. A considerable proportion of SFS cannot be medically explained. The lack of knowledge of its origin and treatment causes further stress in those affected. Purpose - This study aims to get a better understanding of the psychological background of the condition. Methods - A non-representative community sample (N=335; age: 35.1±13.18 yrs; 75.8% female) completed an English on-line questionnaire assessing somatosensory amplification, health anxiety, modern health worries (MHWs), beliefs concerning the scientific validity of complementary and alternative medicine (CAM), holistic beliefs on health and illness. Results - In multiple binary logistic regression analyses, SFS were associated with CAM related beliefs, somatosensory amplification, and health anxiety after controlling for age and gender. The connection between somatosensory amplification and SFS were completely mediated by health anxiety. No differences between the two groups were found with respect to MHWs, worries about the harmful effects of various artificial components in food, and holistic health beliefs. Discussion: More positive attitudes toward CAM might be based on the lack of conventional treatment, rather than on higher levels of MHWs or a more holistic worldview. Both the existence of symptoms and the presence of health anxiety might be needed for the development and maintenance of SFS. Conclusions - The findings support the notion that somatosensory amplification and health anxiety might play a role in the development and maintenance of SFS.

Clinical Neuroscience

JULY 30, 2017

[Guidelines for the treatment of traumatic brain injury - 2017]

BÜKI András, BARZÓ Pál, DEMETER Béla, KANIZSAI Péter, EZER Erzsébet, TÓTH Péter, HORVÁTH Péter, VARGA Csaba

[Traumatic brain injury (TBI) is recognized to be the main cause of death and disability in the first four decades representing a major socio-economical problem worldwide. Recent communications revealed a particularly worrying image about the quality of care for TBI in Hungary. For any improvement a systematic approach characterized by utilization of scientific evidence based guidelines forming the basis for close monitoring of the actual care are considered a prerequisite. In Hungary the first evidence based guidelines in the field of TBI have been issued by the National Society for Anesthesiology and Intensive Care more than two decades ago followed by joint guidelines of the Hungarian Neurosurgical Society and the Hungarian College of Neurosurgeons. These publications were primarily based on the work of the European Brain Injury Consortium as well as guidelines issued by the Brain Trauma Foundation. Recent renewal of the latter and a need to refresh the outdated national guidelines was met by a call from regulatory authorities to issue the updated version of the Hungarian TBI-guidelines. The present review is aimed to briefly summarize the most fundamental elements of the national head injury guidelines that would hopefully be officially issued in a far more detailed format soon.]

Lege Artis Medicinae

MAY 20, 2017

[Changes of the evaulation of scientific publications and researchers based on Hungarian Science Bibliography]


[Different science-metric indicators are great important in evaluating the work of scientists. The authors present the advantages and disadvantages of evaluation numbers which used in the national science in decades and describe in the last year introduced new evaluation criteria. In addition, they analyze and compare the current requirements of the Hungarian Science Bibliography (MTMT) and the Doctoral Schools of the four Hungarian Medical Sciences. Finally, they seek to find out what changes are to be expected later. ]

Lege Artis Medicinae

MARCH 20, 2017

[Based on recent evidences, for what kind of diseases are the Hungarian thermal waters beneficial?]


[Hungary has extremely favorable geothermal facilities, resulting in a leadership role in the usage of thermal water for medical purposes and for publishing medical studies. In the recent decades, a total of 40 balneological subject studies were published in English language journals with impact factors, among these 25 original articles dealing with musculoskeletal disorders, as well as inflammatory and metabolic parameters, dermatological and gynecological diseases; besides these, five experimental works and ten reviews, editorial letters, and other issues. In addition, 20 papers have been published in Hungarian medical journals on the topic of musculoskeletal disorders, including six double-blind clinical studies and six single-blind studies. Based on the published domestic and foreign publications, as other studies have not refuted, Hungarian mineral waters, irrespective of mineral content and concentration of the water, have pain killing effect at patients suffering from degenerative musculoskeletal disorders, chronic low back pain and sometimes improve the quality of life of the patients. Based on small number of data the sulfur and salt bath may be beneficial for dermatologic and gynecologic disorders, while carbon dioxide bath, dry carbonic snow, and mofetta may be beneficial in cardiac and vascular rehabilitation; radon bath and radon cave affect the endocrine system; however, to prove it, a study of a large number of patients are required. ]

Lege Artis Medicinae

FEBRUARY 12, 2017

[Results of the Comprehensive Health Screening of Hungary (MÁESZ) in 2016 and comparative results of 2010-2016]

KISS István, BARNA István, DAIKI Tenno, DANKOVICS Gergely, KÉKES Ede

[In accordance with the Hungarian health strategy, the authors introduce the results of the „Comprehensive Health Screening of Hungary” (MÁESZ) as of 2016 and the comparative results of 2010-2016. It has been again found that the Hungarian population is at high medical risk from multiple perspectives. The program is supported by 68 professional-scientific societies as well as by various secretary of states and the ministry. So far it has accomplished the complex screening of 159 576 residents and informed 375 879 residents about the right lifestyle, the protection of health and prevention of diseases on the ground. ]

Clinical Neuroscience

JANUARY 20, 2017

[Magnetic resonance imaging in the course of alemtuzumab and teriflunomide therapy]

MIKE Andrea, KINCSES Zsigmond Tamás, VÉCSEI László

[Our work aimed to review the published results of magnetic resonance imaging (MRI) obtained in the course of alemtuzumab and teriflunomide therapy in multiplex sclerosis. In multiplex sclerosis MRI sensitively detects subclinical pathological processes, which do not manifest clinically in the early course of the disease, however have substantial significance from the viewpoint of the long-term disease prognosis. MRI has an increasingly important role in the early monitoring of the therapeutic efficacy. In the last 15 years several clinical trials have been conducted with alemtuzumab and teriflunomide in multiple sclerosis providing evidence about the favourable clinical effect of these drugs. MRI images were acquired in these trials as well, and the results published recently in the scientific literature. These MRI results denote the suppression of the disease activity and the neurodegenerative processes, which may imply a favourable effect on the long-term prognosis of the disease. ]

Lege Artis Medicinae

OCTOBER 20, 2016

[“Yesterday no longer exists either…” - End-of-life ethical issues in the care of dementia patients]


[The number of dementia patiens is rising. Most of them die in various institutions, often after many years of care. The long process of nursing and care entails particular ethical requirements that are built primarily on vulnerability, dignity, and dia-logue. The dialogue, however, is often absent from the care of dementia patients. Do we find - as physicians, patients, relatives - that specific time when the patients can still make decisions about end-of-life treatments in a good mental state? Most patients would like to participate in these decisions. Talking about these issues in the early stage of dementia may help in the great emotional burden of family members and caregivers. Therefore the ethical aim is the ad­vance care planning (ACP) of the end-of-life treatments. The study reviews the latest scientific results, with special regard to resources that may be helpful in the course of conversations between doctor and patient on end-of-life preferences, and in the preparation for decision making. ]

Lege Artis Medicinae

OCTOBER 20, 2016

[Basics of the medical use of ayahuasca: physiology of dimethyltryptamine]


[Ayahuasca is a brew made of two admixture plants containing dimethyltryptamine (DMT) and b-carbolines (harmine and tetrahydroharmine). The indigenous groups of the Amazonas basin have been using it for centuries as an ethnomedical substance in healing and spiritual-religious rituals. During the last two decades the brew has raised increased scientific and public interest worldwide about its healing effects. Present paper addresses the therapeutic potentials of ayahuasca use and outlines the cellular mechanisms behind - in focus of the s-1 receptor mediated action of DMT. The scientific investigation of ayahuasca is complicated by methodical problems, legal issues, and sociocultural preconceptions.]

Lege Artis Medicinae

MARCH 20, 2016

[Clinical trials for evaluating cardiovascular safety of SGLT-2- inhibitor drugs in patients with type 2 diabetes]


[SGLT-2-inihibitors are considered as a new class among oral antidiabetic drugs. The first derivatives of this class became available in the last couple of years in Hungary. According to the requirements from regulatory bodies, randomized, controlled clinical trials have been initiated in order to evaluate the cardiovascular safety of nearly all new antidiabetic drugs in patients with type 2 diabetes. Among SGLT-2-inhibitors, only one trial with empagliflozine has been completed so far. Based on the endpoints of the EMPA-REG OUTCOME trial a significant decrease in different cardiovascular events and total mortality was observed in type 2 diabetic patients with elevated cardiovascular risk. The exact pathomechanism of this beneficial effect has not been clearly understood. Currently, the position statements and scientific guidelines clearly describe the place of SGLT-2-inhibitor drugs in the treatment algorithm; the beneficial effect of empagliflozine on cardiovascular events should seriously be considered when making therapeutic decision. Together with the results of ongoing studies with SGLT-2-inhibitors (dapagliflozine: DECLARE, canagliflozine: CANVAS), these data will provide a more robust evidence about the cardiovascular safety of this new class of oral antidiabetic drugs. ]